Alcohol-metabolizing Enzymes' Gene Polymorphisms and Susceptibility to Multiple Head and Neck Cancers

Multiple primary tumors (MPT), especially in the hypopharynx and esophagus, are challenging in patients with head and neck cancer (HNC). Alcohol and alcohol-metabolizing genes were reported to be related to upper digestive tract cancers. Here, we investigated whether the genotypes of alcohol-metabol...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer prevention research (Philadelphia, Pa.) Pa.), 2019-04, Vol.12 (4), p.247-254
Hauptverfasser: Chien, Huei-Tzu, Young, Chi-Kuang, Chen, Tzu-Ping, Liao, Chun-Ta, Wang, Hung-Ming, Cheng, Sou-De, Huang, Shiang-Fu
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Multiple primary tumors (MPT), especially in the hypopharynx and esophagus, are challenging in patients with head and neck cancer (HNC). Alcohol and alcohol-metabolizing genes were reported to be related to upper digestive tract cancers. Here, we investigated whether the genotypes of alcohol-metabolizing enzymes (ADH1B, ADH1C, and ALDH2) affected patients' susceptibility to developing MPTs. We recruited 659 male patients with HNC between March 1996 and February 2017. Age- and gender-matched controls were also recruited. A total of 164 patients with HNC were identified to have second or third malignancies. The single-nucleotide polymorphisms in (rs1229984), (rs698), and (rs671) were analyzed by TaqMan assays. The prevalence of allele carriers is significantly higher than that of homozygotes for oral cavity ( = 0.013) and oropharyngeal cancers ( = 0.012). For , the number of allele carriers is significantly higher than that of homozygotes for oropharyngeal ( = 0.017) and hypopharyngeal cancers ( < 0.001). (rs698) SNPs are not significantly associated with tumor subsites (all > 0.05). Polymorphisms in ( allele carriers) and ( allele carriers) significantly increase the risk of developing MPTs in the upper digestive tract [ < 0.001, OR (95% confidence interval (CI): 5.186 (2.444-11.004) and < 0.05, OR (95% CI): 2.093 (1.149-3.812), respectively]. (rs671) and (rs1229984) allele carriers were shown to develop MPTs in the upper digestive tract. Genetic information may be used to identify high-risk patients for the development of MPTs.
ISSN:1940-6207
1940-6215
DOI:10.1158/1940-6207.CAPR-18-0449